Search results for "Bioinformatic"

showing 10 items of 1651 documents

Overview of key molecular and pharmacological targets for diabetes and associated diseases

2021

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by c…

0301 basic medicineDrugmedia_common.quotation_subjectDiseaseType 2 diabetesBioinformatics030226 pharmacology & pharmacyGeneral Biochemistry Genetics and Molecular BiologyNephropathyDiabetes Complications03 medical and health sciences0302 clinical medicineDiabetes mellitusDrug DiscoveryDiabetes MellitusAnimalsHumansHypoglycemic AgentsMedicineMolecular Targeted TherapyPharmacology & PharmacyGeneral Pharmacology Toxicology and Pharmaceuticsmedia_commonGlycemicbusiness.industry0601 Biochemistry and Cell Biology 1115 Pharmacology and Pharmaceutical SciencesGeneral MedicineMolecular PharmacologyA300medicine.diseaseHuman genetics030104 developmental biologybusinessSignal Transduction
researchProduct

Myotonic dystrophy type 1 drug development: A pipeline toward the market

2021

Highlights • Myotonic dystrophy, a neuromuscular disease, affects at least around half a million people worldwide. • Close to two dozen preclinical and clinical drug development programs active. • Drugs encompass new chemical entities, repurposing, oligonucleotide, and gene therapy. • Tideglusib, mexiletine, and metformin are close to reaching marketing authorization.

0301 basic medicineDrugmedia_common.quotation_subjectMyotonic dystrophyDiseaseBioinformaticsMarketing authorizationMyotonic dystrophy03 medical and health sciences0302 clinical medicineGene therapyDrug DevelopmentDrug DiscoveryMedicineAnimalsHumansAntisense oligonucleotideRepurposingmedia_commonPharmacologybusiness.industryRepurposing drugmedicine.diseaseClinical trialClinical trialDrug repositioning030104 developmental biologyDrug development030220 oncology & carcinogenesisbusinessPost-Screen (Grey)Drug Discovery Today
researchProduct

Advances in drug-induced cholestasis: Clinical perspectives, potential mechanisms and in vitro systems

2018

Despite growing research, drug-induced liver injury (DILI) remains a serious issue of increasing importance to the medical community that challenges health systems, pharmaceutical industries and drug regulatory agencies. Drug-induced cholestasis (DIC) represents a frequent manifestation of DILI in humans, which is characterised by an impaired canalicular bile flow resulting in a detrimental accumulation of bile constituents in blood and tissues. From a clinical point of view, cholestatic DILI generates a wide spectrum of presentations and can be a diagnostic challenge. The drug classes mostly associated with DIC are anti-infectious, anti-diabetic, anti-inflammatory, psychotropic and cardiov…

0301 basic medicineDrugmedicine.drug_classmedia_common.quotation_subjectReceptors Cytoplasmic and NuclearMiscellaneous DrugsIn Vitro TechniquesToxicologyBioinformaticsBile flow03 medical and health sciences0302 clinical medicineCholestasismedicineAnimalsBileHumansDrug induced cholestasismedia_commonCholestasisPolymorphism GeneticBile acidbusiness.industryMembrane Transport ProteinsGeneral Medicinemedicine.diseaseGastrointestinal MicrobiomeMicroRNAs030104 developmental biologyCardiovascular agent030211 gastroenterology & hepatologyChemical and Drug Induced Liver InjurybusinessFood ScienceHealthcare systemFood and Chemical Toxicology
researchProduct

Bisphosphonates, vitamin D, parathyroid hormone, and osteonecrosis of the jaw. Could there be a missing link?

2016

It is estimated that over 190 million bisphosphonates have been prescribed worldwide. But this drug can produce adverse effects, of which osteonecrosis of the jaw and severe hypocalcemia are the most serious. It is evident that bisphosphonate administration affects multiple and diverse biochemical mediators related to bone metabolism. This review of literature investigates four basic parameters in patients treated with bisphosphonates - parathyroid hormone (PTH), bisphosphonates, vitamin D, calcium, and jaw osteonecrosis - which are fundamental for assessing bone metabolism and so the efficacy and correct use of the drug. The imbalances generated by vitamin D and calcium deficiencies, toget…

0301 basic medicineDrugmedicine.medical_specialtymedia_common.quotation_subjectmedicine.medical_treatmentParathyroid hormoneOdontologíaReviewBioinformaticsBone remodeling03 medical and health sciences0302 clinical medicineInternal medicineVitamin D and neurologyHumansMedicineVitamin DAdverse effectGeneral Dentistrymedia_commonBisphosphonate-associated osteonecrosis of the jawDiphosphonatesbusiness.industry030206 dentistryBisphosphonate:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseCiencias de la salud030104 developmental biologyEndocrinologyOtorhinolaryngologyParathyroid HormoneUNESCO::CIENCIAS MÉDICASBisphosphonate-Associated Osteonecrosis of the JawSurgeryOral SurgerybusinessOsteonecrosis of the jawMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.

2020

International audience; Epigenetic enzymes histone deacetylases (HDACs) are clinically validated anticancer drug targets which have been studied intensively in the past few decades. Although several drugs have been approved in this field, they are still limited to a subset of hematological malignancies (in particular T-cell lymphomas), with therapeutic potential not fully realized and the drug-resistance occurred after a certain period of use. To maximize the therapeutic potential of these classes of anticancer drugs, and to extend their application to solid tumors, numerous combination therapies containing an HDACi and an anticancer agent from other mechanisms are currently ongoing in clin…

0301 basic medicineDual targeting[SDV]Life Sciences [q-bio]Cancer therapyKinasesAntineoplastic AgentsBioinformaticsBiochemistryAnticancer drugsSynergistic effectsHistone Deacetylases03 medical and health sciences0302 clinical medicineDrug Delivery SystemsNeoplasmsReceptorsmedicineAnimalsHumansEpigeneticsPharmacologybiologybusiness.industryCancerDUAL (cognitive architecture)medicine.diseaseAnticancer drug3. Good healthEnzymesClinical trial[SDV] Life Sciences [q-bio]Histone Deacetylase Inhibitors030104 developmental biologyHistone030220 oncology & carcinogenesisbiology.proteinHistone deacetylases (HDACs)EpigeneticsDual inhibitorbusinessBiochemical pharmacology
researchProduct

Beneficial Role of Exercise in the Modulation of

2021

Duchenne muscular dystrophy (DMD) is an X-linked recessive progressive lethal disorder caused by the lack of dystrophin, which determines myofibers mechanical instability, oxidative stress, inflammation, and susceptibility to contraction-induced injuries. Unfortunately, at present, there is no efficient therapy for DMD. Beyond several promising gene- and stem cells-based strategies under investigation, physical activity may represent a valid noninvasive therapeutic approach to slow down the progression of the pathology. However, ethical issues, the limited number of studies in humans and the lack of consistency of the investigated training interventions generate loss of consensus regarding …

0301 basic medicineDuchenne muscular dystrophyPhysiologyDuchenne muscular dystrophyClinical BiochemistryInflammationReviewBioinformaticsmedicine.disease_causeBiochemistrySettore BIO/09 - FisiologiaMuscle hypertrophy03 medical and health sciencesTherapeutic approach0302 clinical medicineFibrosismedicineTrainingMuscle inflammationVoluntary exerciseMolecular BiologySwimmingbiologybusiness.industrylcsh:RM1-950ROSCell Biologymedicine.diseaselcsh:Therapeutics. Pharmacology030104 developmental biologyantioxidantsTreadmill runningbiology.proteinmedicine.symptomAntioxidantDystrophinExercise prescriptionbusiness030217 neurology & neurosurgeryOxidative stressAntioxidants (Basel, Switzerland)
researchProduct

Retene causes multifunctional transcriptomic changes in the heart of rainbow trout (Oncorhynchus mykiss) embryos

2015

Fish are particularly sensitive to aryl hydrocarbon receptor (AhR)-mediated developmental toxicity. The molecular mechanisms behind these adverse effects have remained largely unresolved in salmonids, and for AhR-agonistic polycyclic aromatic hydrocarbons (PAHs). This study explored the cardiac transcriptome of rainbow trout (Oncorhynchus mykiss) eleuteroembryos exposed to retene, an AhR-agonistic PAH. The embryos were exposed to retene (nominal concentration 32 μg/L) and control, their hearts were collected before, at and after the onset of the visible signs of developmental toxicity, and transcriptomic changes were studied by microarray analysis. Retene up- or down-regulated 122 genes. Th…

0301 basic medicineEmbryo Nonmammaliananimal structuresHealth Toxicology and Mutagenesista1172Developmental toxicityProtein metabolismdioxin-like toxicityEmbryonic Development010501 environmental sciencesToxicologyBioinformatics01 natural sciencesTranscriptome03 medical and health scienceschemistry.chemical_compoundfish embryotranscriptomicsAnimalsOligonucleotide Array Sequence Analysis0105 earth and related environmental sciencesPharmacologyRetenebiologyGene Expression Profilingta1184ta1182Gene Expression Regulation DevelopmentalHeartLipid metabolismGeneral MedicinePhenanthrenesAryl hydrocarbon receptorCell biology030104 developmental biologychemistryOncorhynchus mykissbiology.proteinta1181Rainbow troutSignal transduction
researchProduct

Metabolic classification and intervention opportunities for tumor energy dysfunction

2021

A comprehensive view of cell metabolism provides a new vision of cancer, conceptualized as tissue with cellular-altered metabolism and energetic dysfunction, which can shed light on pathophysiological mechanisms. Cancer is now considered a heterogeneous ecosystem, formed by tumor cells and the microenvironment, which is molecularly, phenotypically, and metabolically reprogrammable. A wealth of evidence confirms metabolic reprogramming activity as the minimum common denominator of cancer, grouping together a wide variety of aberrations that can affect any of the different metabolic pathways involved in cell physiology. This forms the basis for a new proposed classification of cancer accordin…

0301 basic medicineEndocrinology Diabetes and MetabolismMetabolic reprogrammingReviewBiologyBioinformaticsBiochemistryMicrobiology03 medical and health sciences0302 clinical medicinetumor reprogrammingmedicinetumor microenvironmentMolecular BiologyTumor ecosystemTumor reprogrammingTumor microenvironmentCancerCommon denominatorMetabolismHypoxia (medical)medicine.diseaseQR1-502Metabolic pathway030104 developmental biologyCell metabolismTumor microenvironment030220 oncology & carcinogenesistumor ecosystemmedicine.symptom
researchProduct

miRNA as New Regulatory Mechanism of Estrogen Vascular Action

2018

The beneficial effects of estrogen on the cardiovascular system have been reported extensively. In fact, the incidence of cardiovascular diseases in women is lower than in age-matched men during their fertile stage of life, a benefit that disappears after menopause. These sex-related differences point to sexual hormones, mainly estrogen, as possible cardiovascular protective factors. The regulation of vascular function by estrogen is mainly related to the maintenance of normal endothelial function and is mediated by both direct and indirect gene transcription through the activity of specific estrogen receptors. Some of these mechanisms are known, but many remain to be elucidated. In recent …

0301 basic medicineEstrogen receptorReview030204 cardiovascular system & hematologyBioinformaticsEpigenesis Geneticlcsh:Chemistry0302 clinical medicinelcsh:QH301-705.5Spectroscopyestrogen receptorsGeneral MedicineComputer Science ApplicationsMenopauseReceptors EstrogenRNA InterferenceDisease Susceptibilitymedicine.drug_classCèl·lulesBiologyepigenetic regulationCatalysisCardiovascular Physiological PhenomenaInorganic Chemistry03 medical and health sciencesestradiolmicroRNAmedicineAnimalsHumansEpigeneticsPhysical and Theoretical ChemistryMolecular BiologyGenemiRNAReceptors d'hormonesMechanism (biology)Organic ChemistryEndothelial CellsEstrogensmedicine.diseaseMicroRNAs030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Gene Expression RegulationEstrogenBlood VesselsFunction (biology)Genètica
researchProduct

De novo transcriptome assembly and its annotation for the aposematic wood tiger moth (Parasemia plantaginis)

2017

In this paper we report the public availability of transcriptome resources for the aposematic wood tiger moth (Parasemia plantaginis). A comprehensive assembly methods, quality statistics, and annotation are provided. This reference transcriptome may serve as a useful resource for investigating functional gene activity in aposematic Lepidopteran species. All data is freely available at the European Nucleotide Archive (http://www.ebi.ac.uk/ena) under study accession number: PRJEB14172. Peer reviewed

0301 basic medicineEuropean Nucleotide Archivelcsh:QH426-470De novo transcriptome assemblyZoologyspeciesAposematismBiochemistryTranscriptome03 medical and health sciencesAnnotationParasemia plantaginisGeneticsta119biologyTiger1184 Genetics developmental biology physiologywood tiger mothAccession number (bioinformatics)biology.organism_classificationlcsh:Genetics030104 developmental biologyEvolutionary biology1181 Ecology evolutionary biologyMolecular Medicineta1181BiotechnologyGenomics Data
researchProduct